



Nicox completes the acquisition of Eupharmed

December 6, 2013

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Eupharmed, a privately-held Italian ophthalmic company. This acquisition is part of Nicox's strategy to establish sales infrastructure in the five major European markets and in the United States as it provides an established sales and marketing platform in Italy together with a broad portfolio of marketed eye care products.

For more information, please refer to:

- Press release dated November 26, 2013: [Nicox establishes commercial operations in Italy through acquisition of Eupharmed](#)
 - Press release dated December 5, 2013 (Art. 12 of the AMF instruction 2005-11) (in French): [Emission par Nicox de 1.351.351 actions et de 1.500.000 bons d'attribution d'actions en rémunération de l'apport de la totalité du capital de la société Eupharmed](#)
-



About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).

.....



Contacts

Nicox

Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

FTI Consulting

Europe

Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263
Julia.Phillips@fticonsulting.com
Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0) 7843 080947
Stephanie.Cuthbert@fticonsulting.com
Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977
Mo.Noonan@fticonsulting.com